Pakseresht, Arash
Novo Nordisk (Denmark)
4 papers on CoChat
Most cited papers
- Verified
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 1,419
- Verified
Perceptions of barriers to effective obesity management in Canada: Results from the ACTION study
Sharma, A. M., Bélanger, A., Carson, V., Krah, J., Langlois, M., Lawlor, D., Lepage, S., Liu, A., Macklin, D. A., MacKay, N., et al. (2019) · Clinical Obesity
Obesity and Health PracticesObesity, Physical Activity, Diet
Cited by 86
- Verified
Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
Wharton, S., Liu, A., Pakseresht, A., Nørtoft, E., Haase, C. L., Mancini, J., Power, G. S., Vanderlelie, S., & Christensen, R. A. G. (2019) · Obesity
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 77
- Verified
Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada
Wharton, S., Haase, C. L., Kamran, E., Liu, A., Mancini, J., Neish, D., Pakseresht, A., Power, G. S., & Christensen, R. A. G. (2020) · Obesity Science & Practice
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 26
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free